Print

Amarin Corporation PLC (AMRN) Announces Submission of Supplemental New Drug Application for Novasep as Fourth Vascepa® Active Pharmaceutical Ingredient Supplier  
8/26/2013 9:37:42 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 26, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the submission of a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for Novasep Group, S.A.S., through its subsidiary Finorga S.A.S., as an additional Vascepa® (icosapent ethyl) active pharmaceutical ingredient (API) supplier. Novasep is part of the previously disclosed Slanmhor consortium with which Amarin announced a global supply agreement in 2012.

Help employers find you! Check out all the jobs and post your resume.

//-->